<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Res Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Res Med Sci</journal-id><journal-id journal-id-type="publisher-id">JRMS</journal-id><journal-title-group><journal-title>Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1735-1995</issn><issn pub-type="epub">1735-7136</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25657746</article-id><article-id pub-id-type="pmc">4310074</article-id><article-id pub-id-type="publisher-id">JRMS-19-1034</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (Thromboangiitis Obliterans)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Beigi</surname><given-names>Ali Akbar</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Hoghoughi</surname><given-names>Mohammad Ali</given-names></name><xref ref-type="aff" rid="aff2">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Eshaghian</surname><given-names>Afrooz</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Zade</surname><given-names>Akbar Hassan</given-names></name><xref ref-type="aff" rid="aff4">3</xref></contrib><contrib contrib-type="author"><name><surname>Masoudpour</surname><given-names>Hassan</given-names></name><xref ref-type="aff" rid="aff5">4</xref></contrib></contrib-group><aff id="aff1">Department of Vascular Surgery, Saint Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff2"><label>1</label>Department of Surgery, Saint Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff3"><label>2</label>Department of Head and Neck Surgery, Saint Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff4"><label>3</label>Department of Epidemiology and Biostatistics, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff5"><label>4</label>Molecular Structure and Function, Research Institute, The Hospital for Sick Children, University of Toronto, Ontario, Canada</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Mohammad Ali Hoghoughi, Department of Surgery, Saint Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: <email xlink:href="hoghoughima@yahoo.com">hoghoughima@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2014</year></pub-date><volume>19</volume><issue>11</issue><fpage>1034</fpage><lpage>1037</lpage><history><date date-type="received"><day>07</day><month>3</month><year>2014</year></date><date date-type="rev-recd"><day>13</day><month>9</month><year>2014</year></date><date date-type="accepted"><day>17</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Journal of Research in Medical Sciences</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>The mechanism underlying Buerger's disease (BD) is still unknown. Recently, thrombophilic conditions predisposing to a hypercoagulable state have been hypothesized as triggers for BD. The aim of the study is to evaluate the prevalence of the hyperhomocysteinemia and level of the anticardiolipin antibodies, and the role of folic acid on the hyperhomocysteinemia and on the rate of the amputations in the patients with BD.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>In an experimental placebo-controlled double-blinded study, between 2004 and 2010, thirty patients with BD were randomly assigned into two groups (14 patients in a drug group and 16 patients in the placebo group). Drug or placebo was administered, and they were followed in 2 and 6 months for homocysteine, Anticardiolipin antibodies and the risk of amputations.</p></sec><sec id="st3"><title>Results:</title><p>At the beginning of the study homocysteine level was higher than normal in 19 patients (63%). There was a significant decrease in homocysteine level during 6 months in folic acid group (<italic>P</italic> &#x0003c; 0.001), but there was no change in the placebo group. None of our patients had elevated Anticardiolipin antibodies, and there was no change in the level of Anticardiolipin antibody during study. High level of homocysteine did not associate with more amputations during 6 months of study (<italic>P</italic> &#x0003e; 0.05).</p></sec><sec id="st4"><title>Conclusion:</title><p>This study shows the hyperhomocysteinemia in BD, and the benefit of folic acid treatment in homocysteine lowering, but folic acid doesn&#x02019;t inhibit the risk of major and minor amputation during 6 months of follow-up. Longer follow-up may reveal the role of folic acid in these patients</p></sec></abstract><kwd-group><kwd>Anticardiolipin antibodies</kwd><kwd>Buerger's disease</kwd><kwd>folic acid</kwd><kwd>hyperhomocysteinemia</kwd><kwd>thromboangiitis obliterans</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Thromboangiitis Obliterans or Buerger's disease (BD) is a chronic nonatherosclerotic inflammatory obliterative disease which affects predominantly small and medium arteries and veins in the infra-popliteal and infra-brachial regions. Although BD has a worldwide distribution, nowadays it is more prevalent in the middle east and far east than in North America and Western Europe.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref>] It is seen more common in the young smoker men and in a low socioeconomic status.[<xref rid="ref5" ref-type="bibr">5</xref>] BD is established on the basis of the clinical presentation and physical findings, according to the following criteria; history of smoking (current or recent), onset of disease before 50 years old, infra-popliteal obliterative arterial involvement, upper limb involvement or phlebitis migrans, and absence of atherosclerosis risk factors other than smoking.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref>] There is no specific diagnostic laboratory indicator, so in those countries where the BD is common, the clinical criteria of Shionoya are accepted.[<xref rid="ref3" ref-type="bibr">3</xref>] However, in countries with a rare incidence of BD, the diagnosis is based on imaging and by excluding other vasculitis, using expensive laboratory tests.</p><p>Etiology and pathogenesis of BD is not completely understood, but environmental predisposing factors such as genetic and nicotine was supposed.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>] After smoking and tobacco cessation, other medical or surgical therapies have limited results.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>]</p><p>Another possible pathogenesis observed in the patients with BD is a hemostatic disturbance. Hyperhomocysteinemia is common in BD, and may have an important effect on BD pathogenesis irrelevant to Nicotine.[<xref rid="ref5" ref-type="bibr">5</xref>] Preliminary data have been shown hyperhomocysteinemia is a risk factor for venous thrombosis[<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref>] aggravates the prognosis, and may reveal that the patients undergo amputation earlier.[<xref rid="ref8" ref-type="bibr">8</xref>]</p><p>Unfortunately, prevalence of smoking is very high in our country, and the prevalence of the BD is high as well; in contrast with other Asian countries which encounter one or two new patients per year.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref3" ref-type="bibr">3</xref>] The patients with BD take two in every 20 vascular surgery beds at St. Zahra Hospital. About 23% of the ischemic patients &#x0003c;50 years old who referred to our vascular clinic are diagnosed with Burger's disease. Also, we see many complications related to disease as a result of late diagnosis and treatment, but many of our patients could not stop smoking, and have no ideal treatment response.</p><p>It has been hypothesize that hypercoagulability state (like hyperhomocysteinemia, increased anticardiolipin, and genetic factors) has a role in the pathophysiology of BD.[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>] It has been established that Folic acid could improve hyperhomocysteinemia;[<xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>] Also Folic acid could improve endothelial function as a result of lowering homocysteine, and might have a beneficial effect on BD. This study was done to evaluate the role of homocysteine lowering effect of Folic acid on limb amputation, the major complication of BD.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><p>This was an experimental placebo controlled double-blinded study. The study group was 30 identified Buerger's patients based on the criteria who were randomly allocated in drug or placebo groups (14 patients in drug group and 16 patients in placebo group) from January 2004 to January 2010. All of them were advised stop smoking and were on standard routine treatment protocol of BD. To confirm the smoking cessation, urine check was done. All participants signed informed consent. The study was approved by Isfahan University of Medical Sciences Ethics Committee, Isfahan, Iran. It was registered in Iranian Registry of Clinical trials (IRCT201108012106N2).</p><p>The inclusion criteria contained negative history of hypertension, diabetes mellitus, ischemic heart disease, cerebrovascular disease or collagen vascular disease as well as negative vasculitis workup. The exclusion criteria were surgical sympathectomy or any sort of vascular bypass; using aspirin, calcium channel blocker, B6 or B12; stop smoking during the study and have not compliance of being treated. Also, patients with hypercoagulative state due to inherited thrombophilia (factor V Leiden, A202120G prothrombin variant, acquired activated protein C resistance, protein C and S deficiency, antithrombin deficiency were excluded from the study.</p><p>Medication was one oral 5 mg folic acid tablet (Jallinus Pharmacy, Tehran, Iran) and placebo (Amin Pharmacy, Isfahan, Iran) with the same as the color, size, weight, and box.</p><p>At the start of the study, we measured demographic data, homocysteine and Anticardiolipin level in the form. Following administration of drug and placebo, they were followed 2 and 6 months later. Lab data, minor or major amputations were recorded during follow-up.</p><p>At the end of the study, data were analyzed by SPSS version 17 (SPSS Inc., Chicago, USA) by Chi-square, <italic>t</italic>-test, covariance analysis, repeated measure ANOVA, Freidman, Wilkaxon and Mann&#x02013;Whitney tests.</p></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>This study contained 30 patients (14 in Folic acid group and 16 in the placebo group) [<xref ref-type="table" rid="T1">Table 1</xref>]. All of them were male. None of the patients had a history of diabetes mellitus, chronic renal failure, ischemic heart disease, and hypertension. Only two patients had a history of hyperlipidemia. Except years of education, other baseline characteristics didn&#x02019;t have a difference between two groups (<italic>P</italic> &#x0003e; 0.05).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic parameters in two groups</p></caption><graphic xlink:href="JRMS-19-1034-g001"/></table-wrap><p>At the beginning of the study, 19 patients (63%) had homocysteine level higher than normal (normal value was 15 mg/dl). None of our patients had elevated anticardiolipin antibody. By one sample <italic>t</italic>-test, baseline homocysteine level at baseline was more than normal value in Buerger's patients (<italic>P</italic> = 0.002). The Baseline level of homocysteine and anticardiolipin antibody was not different between two groups (<italic>P</italic> &#x0003e; 0.05) [Tables <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>].</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>The mean of homocysteine level at the baseline, 2<sup>nd</sup> and 6<sup>th</sup> month of study</p></caption><graphic xlink:href="JRMS-19-1034-g002"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>The mean of anticardiolipin level at the baseline, 2<sup>nd</sup> and 6<sup>th</sup> months</p></caption><graphic xlink:href="JRMS-19-1034-g003"/></table-wrap><p>Because the baseline of the homocysteine level was higher in folic acid group (that was not significant), covariance analysis was performed, and it demonstrated that the folic acid was more effective from the 2<sup>nd</sup> month of study.</p><p>We divided the patients into two normal and high level of homocysteine groups; and compared the major and minor limb amputations in each placebo and folic acid groups at the beginning, 2<sup>nd</sup> and 6<sup>th</sup> month. High level of homocysteine did not increase amputations during 6 months of study (<italic>P</italic> &#x0003e; 0.05) [<xref ref-type="table" rid="T4">Table 4</xref>]. Anticardiolipin antibody did not change in level during 6 months of study in none of the folic acid and placebo groups (<italic>P</italic> &#x0003e; 0.05).</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>The number of major and minor amputation in both groups</p></caption><graphic xlink:href="JRMS-19-1034-g004"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>This study revealed 63% prevalence of hyperhomocysteinemia in our Buerger's patients that was higher than previous reports, which was 23% in Stammlers study[<xref rid="ref3" ref-type="bibr">3</xref>] and 60% in Deiham study.[<xref rid="ref8" ref-type="bibr">8</xref>]</p><p>This study have been shown the benefit of folic acid on homocysteine lowering in Buerger's disease but not on Anticardiolipin level. The studies show 10 mg folic acid for 4 weeks in patients with hyperhomocysteinemia (more than 75 percentile) and without cardiovascular risk factors could improve arterial endothelial function and decrease homocysteine.[<xref rid="ref9" ref-type="bibr">9</xref>] There was no change for independent endothelial vasodilatation. No side effect had been reported.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref9" ref-type="bibr">9</xref>]</p><p>Two studies had been shown that endothelial function didn&#x02019;t improve with homocysteine lowering;[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref14" ref-type="bibr">14</xref>] but another one revealed the lower homocysteine is a protective vascular factor irrelevant to folate.[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref15" ref-type="bibr">15</xref>] Impaired endothelial function is assumed as a predisposing factor in BD[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref>] and we hypothesized that the folic acid may improve vasculature endothelium and could decrease amputation. In present study, high level of homocysteine did not associate with more amputations after 6 months of study in either placebo or folic acid group; and we could not follow our supposition. This pilot result can be attributed to short follow-up or small sample size.</p><p>As in our results, previous studied revealed folic acid, Vitamin B6 and B12 could not inhibit major cardiovascular complications and recurrent venous thrombosis.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref17" ref-type="bibr">17</xref>]</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>This study shows hyperhomocysteinemia in BD, and the benefit of folic acid in homocysteine lowering; folic acid could not inhibit major and minor amputation during 6 months of follow-up. Longer follow-up may reveal the benefit of folic acid in these patients.</p><p>This study emphasized the role of homocysteine in the pathogenesis of BD, especially in smoker patients. More detailed immunological and endothelial surveys can clarify this hypothesis.</p></sec><sec id="sec1-6"><title>AUTHOR'S CONTRIBUTION</title><p>All authors have contributed in designing and conducting the study. All authors have assisted in preparation of the first draft of the manuscript or revising it critically for important intellectual content. All authors have read and approved the content of the manuscript and confirmed the accuracy or integrity of any part of the work.</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>We thank Dr. Maryam Ghassami for her collaboration in preparing the proposal of the study.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein-Weigel</surname><given-names>PF</given-names></name><name><surname>Richter</surname><given-names>JG</given-names></name></person-group><article-title>Thromboangiitis obliterans (Buerger's disease)</article-title><source>Vasa</source><year>2014</year><volume>43</volume><fpage>337</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">25147010</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Chaer</surname><given-names>RA</given-names></name></person-group><article-title>Nonarteriosclerotic vascular disease</article-title><source>Surg Clin North Am</source><year>2013</year><volume>93</volume><fpage>833</fpage><lpage>75</lpage><comment>viii</comment><pub-id pub-id-type="pmid">23885934</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cronenwett</surname><given-names>JL</given-names></name><name><surname>Johnston</surname><given-names>KW</given-names></name><name><surname>Rutherford</surname><given-names>RB</given-names></name><name><surname>Ebrary</surname><given-names>Inc</given-names></name></person-group><article-title>Rutherford's Vascular Surgery</article-title><year>2010</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>Saunders/Elsevier</publisher-name><comment>Available from:
<uri xlink:type="simple" xlink:href="https://expertconsult.inkling.com/store/book/cronenwett-rutherfords-vascular-surgery-2-volume-set-8th/">https://expertconsult.inkling.com/store/book/cronenwett-rutherfords-vascular-surgery-2-volume-set-8th/</uri></comment></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavakoli</surname><given-names>H</given-names></name><name><surname>Rezaii</surname><given-names>J</given-names></name><name><surname>Esfandiari</surname><given-names>K</given-names></name><name><surname>Salimi</surname><given-names>J</given-names></name><name><surname>Rashidi</surname><given-names>A</given-names></name></person-group><article-title>Buerger's disease: A 10-year experience in Tehran, Iran</article-title><source>Clin Rheumatol</source><year>2008</year><volume>27</volume><fpage>369</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">18172574</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenari</surname><given-names>AY</given-names></name><name><surname>Karimi</surname><given-names>M</given-names></name><name><surname>Salimi</surname><given-names>J</given-names></name><name><surname>Khashayar</surname><given-names>P</given-names></name></person-group><article-title>Plasma levels of homocysteine in Buerger's sufferers and healthy heavy smokers and non-smokers</article-title><source>Clin Lab</source><year>2013</year><volume>59</volume><fpage>93</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">23505912</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramin</surname><given-names>M</given-names></name><name><surname>Salimi</surname><given-names>J</given-names></name><name><surname>Meysamie</surname><given-names>A</given-names></name></person-group><article-title>An Iranian scoring system for diagnosing Buerger's disease</article-title><source>Acta Med Iran</source><year>2014</year><volume>52</volume><fpage>60</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">24658990</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazeli</surname><given-names>B</given-names></name></person-group><article-title>Need for changes in clinical criteria for diagnosing Buerger's disease</article-title><source>Vascular</source><year>2013</year><volume>21</volume><fpage>117</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23596184</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazeli</surname><given-names>B</given-names></name><name><surname>Modaghegh</surname><given-names>H</given-names></name><name><surname>Ravrai</surname><given-names>H</given-names></name><name><surname>Kazemzadeh</surname><given-names>G</given-names></name></person-group><article-title>Thrombophlebitis migrans as a footprint of Buerger's disease: A prospective-descriptive study in north-east of Iran</article-title><source>Clin Rheumatol</source><year>2008</year><volume>27</volume><fpage>55</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17554578</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hus</surname><given-names>I</given-names></name><name><surname>Sokolowska</surname><given-names>B</given-names></name><name><surname>Walter-Croneck</surname><given-names>A</given-names></name><name><surname>Chrapko</surname><given-names>M</given-names></name><name><surname>Nowaczynska</surname><given-names>A</given-names></name><name><surname>Dmoszynska</surname><given-names>A</given-names></name></person-group><article-title>Assessment of plasma prothrombotic factors in patients with Buerger's disease</article-title><source>Blood Coagul Fibrinolysis</source><year>2013</year><volume>24</volume><fpage>133</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23358197</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lippi</surname><given-names>G</given-names></name><name><surname>Plebani</surname><given-names>M</given-names></name></person-group><article-title>Hyperhomocysteinemia in health and disease: Where we are now, and where do we go from here ?</article-title><source>Clin Chem Lab Med</source><year>2012</year><volume>50</volume><fpage>2075</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">23093205</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinelli</surname><given-names>I</given-names></name><name><surname>Passamonti</surname><given-names>SM</given-names></name><name><surname>Bucciarelli</surname><given-names>P</given-names></name></person-group><article-title>Thrombophilic states</article-title><source>Handb Clin Neurol</source><year>2014</year><volume>120</volume><fpage>1061</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">24365371</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadir</surname><given-names>Y</given-names></name><name><surname>Hoffman</surname><given-names>R</given-names></name><name><surname>Brenner</surname><given-names>B</given-names></name></person-group><article-title>Association of homocysteine, Vitamin B12, folic acid, and MTHFR C677T in patients with a thrombotic event or recurrent fetal loss</article-title><source>Ann Hematol</source><year>2007</year><volume>86</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">17043779</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glueck</surname><given-names>CJ</given-names></name><name><surname>Haque</surname><given-names>M</given-names></name><name><surname>Winarska</surname><given-names>M</given-names></name><name><surname>Dharashivkar</surname><given-names>S</given-names></name><name><surname>Fontaine</surname><given-names>RN</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Stromelysin-1 5A/6A and eNOS T-786C polymorphisms, MTHFR C677T and A1298C mutations, and cigarette-cannabis smoking: A pilot, hypothesis-generating study of gene-environment pathophysiological associations with Buerger's disease</article-title><source>Clin Appl Thromb Hemost</source><year>2006</year><volume>12</volume><fpage>427</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">17000887</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Micco</surname><given-names>P</given-names></name><name><surname>Niglio</surname><given-names>A</given-names></name><name><surname>Scudiero</surname><given-names>O</given-names></name><name><surname>Bonamassa</surname><given-names>B</given-names></name><name><surname>Martinelli</surname><given-names>I</given-names></name><name><surname>Di Fiore</surname><given-names>R</given-names></name><etal/></person-group><article-title>A case of Buerger's disease associated with MTHFR C677T mutation homozygosity: A possible therapeutic support</article-title><source>Nutr Metab Cardiovasc Dis</source><year>2004</year><volume>14</volume><fpage>225</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15553601</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brazzelli</surname><given-names>V</given-names></name><name><surname>Grasso</surname><given-names>V</given-names></name><name><surname>Fornara</surname><given-names>L</given-names></name><name><surname>Moggio</surname><given-names>E</given-names></name><name><surname>Gamba</surname><given-names>G</given-names></name><name><surname>Villani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Homocysteine, Vitamin B12 and folic acid levels in psoriatic patients and correlation with disease severity</article-title><source>Int J Immunopathol Pharmacol</source><year>2010</year><volume>23</volume><fpage>911</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">20943063</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cacciapuoti</surname><given-names>F</given-names></name></person-group><article-title>Lowering homocysteine levels with folic acid and B-vitamins do not reduce early atherosclerosis, but could interfere with cognitive decline and Alzheimer's disease</article-title><source>J Thromb Thrombolysis</source><year>2013</year><volume>36</volume><fpage>258</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">23224755</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>den</surname><given-names>Heijer M</given-names></name><name><surname>Willems</surname><given-names>HP</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name><name><surname>Gerrits</surname><given-names>WB</given-names></name><name><surname>Cattaneo</surname><given-names>M</given-names></name><name><surname>Eichinger</surname><given-names>S</given-names></name><etal/></person-group><article-title>Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>139</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">16960155</pub-id></element-citation></ref></ref-list></back></article>